STAT49%
ARPA-H invests $160 million to make custom gene editing routine 31%
By Jason Mast0% https:47% www.statnews.com49% #43% schema42% person43% f27e81941b55aae65a8b1304575ad0800%
7/9/2026, 3:00:00 PM
BS Summary: This article contains 1 faulty reasoning type, including Attempt to Sell a Product or Service, with Attempt to Sell a Product or Service as the most egregious example at 21.6% saturation with 61 hits. Analysis detected 61 faulty-reasoning hits from 282 analyzed words, generating a BS Score of 41.7% and a BS Rank of 31% (9,883 of 14,328 articles). This article is better (less manipulative) than 69.00% of the article peer group.
ARPA-H launches $160 million effort to develop custom gene editing drugs
Program will fund seven groups over five years in hope of Baby KJ-like successes
Jean-Christophe VERHAEGEN / AFP via Getty Images
General Assignment Reporter
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease.
Confidential tips can be sent on Signal at JasonMast.77.
ARPA-H, the U.S.’ “moonshot” agency for health research, announced Thursday that it will spend up to $160 million to push forward custom gene editing treatments for a spate of rare diseases.
The program, called THRIVE, will back seven different teams pursuing various groups of conditions affecting different organ systems.
Each team has a deadline of starting clinical trials by year three of the program, although some may start much sooner.
STAT+ Exclusive Story
Already have an account?
Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Totals $468 per year
for 3 months, then $399/year
Savings start at 25%!
$300 Annually per user
To read the rest of this story subscribe to STAT+.
biotechnology , CRISPR , gene editing , Gene therapy , HHS , rare diseases , STAT+
Submit a correction request Reprints
STAT Plus: Roche ends Huntington’s gene-silencing programs
STAT Plus: Prime wins Beam arbitration, clearing path to clinic
Adam's Biotech Scorecard
STAT Plus: 931 days.
The drug approval scandal hiding in plain sight
STAT Plus: AstraZeneca, Ionis report major trial failure with heart disease drug
STAT Plus: The quest to save Grace — and clear the way for rare disease patients everywhere
Speakers
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.